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1. Introduction 
Endoscopic ultrasound (EUS) has revolutionized the field of gastrointestinal endoscopy, and 
it plays a pivotal role in the staging of tumors of the upper gastrointestinal (GI) tract. EUS 
provides high-resolution imaging of both intraluminal and extraluminal structures, 
allowing for the detection and staging of even the smallest tumors in a minimally invasive 
manner. The accuracy of EUS in assessing depth of invasion of luminal tumors (T stage) is 
greater than other imaging modalities, including multi-detector CT and MRI. The addition 
of fine needle aspiration (FNA) allows for assessment of nodal involvement (N stage), and 
although the quality of images obtained by CT and MRI continue to rapidly advance, EUS 
remains essential for obtaining tissue samples and for the definitive diagnosis of lesions 
within or adjacent to the upper GI tract.  
This chapter aims to serve as an evidence-based and comprehensive review used to guide 
endosonographers involved in the care of patients with upper GI tract malignancies. We 
will outline the goals, challenges, and pitfalls encountered during the EUS evaluation for 
cancer staging. Furthermore, we will discuss the endoscopic technique best utilized for 
assessing cancers of the esophagus, stomach, ampulla and duodenum. 
2. Basic EUS principles for staging upper GI tumors 
The expertise of the endosonographer is considered one of the most important aspects in the 
staging of upper GI tract malignancy. A complete understanding of the normal anatomy 
and common congenital anomalies of the organ studied is a prerequisite for an accurate 
examination. Experience in identifying local and regional lymph nodes, and precisely 
assessing the level of tumor invasion, is critical for directing patients into the appropriate 
treatment algorithm; as often the choice of surgical procedure relies upon this information. 
There are several classification systems currently in use for defining GI cancers, predicting 
prognosis and determining treatment. Most commonly used is the tumor, node, metastasis 
(TNM) staging system as described by the American Joint Committee on Cancer (AJCC) [1]. 
The basic technique for performing endoscopic ultrasound for staging is similar for tumors 
located in the esophagus, stomach, and duodenum. We usually begin with standard upper 
endoscopy to visually assess the lesion, to determine whether the larger echoendoscope will 
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be able to traverse the lesion, and to dilate any luminal malignant strictures if necessary. The 
location of the tumor being studied will often direct the choice of radial or linear 
echoendoscope, or whether a   high-frequency ultrasound (HFUS) probe is needed. HFUS 
probes are ultrasound transducers located at the tip of a small-caliber (2 to 2.9 mm) catheter 
that can pass through the working channel of a standard endoscope. They are available in 
frequencies between 12-30 MHz and yield high-resolution images of the gastrointestinal 
wall layers. They are typically used in the evaluation and T staging of small or superficial 
masses. Several studies have shown equivalency to conventional EUS for T staging although 
conventional EUS is superior for nodal staging[2].  
In order to assess depth of invasion (T stage) for luminal tumors, it is necessary to identify 5 
layers of wall structure that correspond to the histological layers (Image 1). HFUS allows for 
the visualization of up to nine layers. Using an echoendoscope at a frequency between 7.5 
and 10 MHz, the 5 layers appear as alternating hyperechoic and hypoechoic bands as 
follows [3, 4]: 
 
 
1st hyperechoic layer: surface mucosa 
2nd hypoechoic layer: deep mucosa 
3rd hyperechoic layer: submucosa 
4th hypoechoic layer: muscularis propria 
5th hyperechoic layer: serosa (or adventitia in the esophagus) 
Image 1. High-frequency probe demonstrating the layers of the gastric wall. 
The EUS characteristics of lymph nodes for prediction of lymph node metastases (N stage) 
were originally described in patients with esophageal cancer. Features suggestive of 
metastatic lymph nodes are size greater than 1 cm, sharp borders, rounded shape, and 
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homogenous hypoechoic echo pattern. When all four of these predictive features were 
found in a single lymph node, lymph node metastases were found in 100% of cases [5]. EUS 
fine-needle aspiration (FNA) adds to the evaluation for malignant lymph nodes by safely 
and accurately providing tissue samples which can influence patient management [6]. 
3. Staging of esophageal tumors 
Esophageal tumors commonly present with symptoms of dysphagia and are often initially 
diagnosed by upper endoscopy. EUS provides superior loco-regional staging compared to 
other imaging modalities, and combined with FNA improves decision making regarding 
surgery and neo-adjuvant therapy [7, 8]. The role of EUS in early esophageal neoplasia is 
more controversial as endoscopic mucosal resection (EMR) may play an important role. 
CT is usually performed early in the staging of esophageal cancers to evaluate for evidence 
of metastatic disease. EUS is indicated for staging of esophageal cancers in the absence of 
distant metastases on initial CT scan or MRI. Determining a T stage is accomplished by EUS 
and the first step for the endosonographer is repeating the standard upper endoscopy. This 
will allow the endosonographer to document the location of the tumor, measure the extent 
of stricture and assess whether the echoendoscope will easily pass the tumor if a stricture 
exists. Inability to pass the echoendoscope beyond a stricture is generally associated with a 
poorer prognosis as it may suggest advanced disease, but an effort should be made to 
traverse strictures as a more accurate T and N stage can be determined [9, 10]. Dilation may 
be performed with either a Savary dilator over the wire, or with a through-the-scope (TTS) 
controlled radial expansion (CRE) dilation balloon. A higher rate of esophageal perforation 
has been reported with dilation of malignant esophageal strictures, but it is generally 
regarded as safe [11, 12]. In our practice, if we experience resistance due to a malignant 
stricture precluding passage of a standard EGD scope or echoendoscope, we dilate with a 
TTS CRE balloon up to 14-16 mm so as to then allow for a complete and thorough staging 
EUS exam. If a high-grade stricture is present, serial dilations may be necessary prior to the 
EUS staging. 
3.1 Determining the T stage 
Assessment of the depth of invasion of the tumor is necessary for determination of a T stage. 
CT and MRI lack the sensitivity to accurately distinguish between the different layers of the 
esophageal wall. EUS has excellent sensitivity and specificity in assessing depth of invasion 
that increases with more advanced tumors (T4 tumors) [13]. The T stage for primary 
adenocarcinomas of the esophagus, esophagogastric junction (EGJ), and esophageal 
squamous cell cancers (SCC) are the same according to the 7th Edition of the TNM staging 
manual of the American Joint Committee on Cancer (AJCC). EGJ tumors are those within 
the first 5 cm of the stomach that extend into the esophagogastric junction or distal thoracic 
esophagus. Non-anatomic classifications (histopathological cell type, histologic grade and 
tumor location) were identified in the latest revision of the manual for stage grouping [14].  
Once the tumor has been identified endoscopically, the echoendoscope should be carefully 
advanced beyond the most distal portion of the tumor. Minimal balloon distention should 
be utilized to minimize compression of the tumor and esophageal wall. Esophageal tumors 
appear as hypoechoic masses with irregular borders and penetration beyond the esophageal 
layers should be described. Measurement of the mass thickness should be noted as it can 
predict extra-esophageal extension [15]. Early esophageal cancers are defined as tumors 
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limited to the mucosa and/or submucosa but not extending into the muscular wall of the 
esophagus (T1)[16]. Tis is the earliest tumor stage and defined as high-grade dysplasia. It 
was previously known as carcinoma-in-situ and includes all noninvasive neoplastic 
epithelium [1, 14]. EUS is not accurate for mucosal evaluation and staging of these early 
lesions, even with the use of high-frequency endoscopic ultrasound probes. Tis lesions are 
best diagnosed by other means, such as endoscopic mucosal resection (EMR) [17]. 
Once a tumor has invaded the lamina propria, muscularis mucosa or submucosa but not 
the muscularis propria, it considered a stage T1 tumor. This stage is further sub-divided 
to T1a (also known as T1m and further subdivided to m1: limited to the epithelial layer, 
m2: invading lamina propria and m3: invading into but not through muscularis mucosa) 
for tumors that invade the lamina propria or muscularis mucosa;  and T1b (also known as 
T1sm and further subdivided into thirds to sm1, sm2 and sm3: deepest one third of the 
submucosa) for tumors that invade the submucosa [1, 13, 18]. The depth of invasion 
predicts the probability of lymph node metastasis, vascular invasion and long-term 
survival [19]. There has been much debate and controversy regarding the staging 
modality for early esophageal cancers. Although EUS can distinguish between stages T1 
and >T1, recent data has shown that EUS is not sufficiently accurate in distinguishing 
between T1a and T1b tumors and pathological staging by EMR should be performed [17, 
20, 21]. Whether EUS should be performed prior to EMR is another debatable topic and 
beyond the scope of this chapter. Small caliber high-frequency EUS probes are able to 
visualize nine esophageal layers and may be able to accurately identify depth of invasion 
to guide therapy [18, 22, 23]. 
 
 
Image 2. T1 esophageal cancer; the muscularis propria can be clearly seen surrounding the 
tumor. 
muscularis propria 
tumor 
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Stage T2 tumors have invaded the fourth hypoechoic layer, the muscularis propria. In a 
recent meta-analysis, the diagnostic accuracy of EUS in staging of a T2 tumor was found to 
have a sensitivity of 81.4% and specificity of 96.3% [13]. The distinction between a T2 and T3 
tumor is important in the decision for neoadjuvant therapy [24]. The endosonographer 
needs to be cautioned that overstaging of T2 tumors can lead to the inappropriate use of 
neoadjuvant therapy instead of immediate surgery [25]. 
EUS has its highest accuracy in staging advanced tumors. The distinction between a T3 
(tumor invading adventitia, or going through the muscularis propria) and a T4 (tumor 
invading adjacent structures) is important in that it can determine resectability [1, 7, 14]. In 
the latest revision of the AJCC Staging Manual, T4 tumors were divided into resectable 
tumors (T4a) and unresectable (T4b). Those tumors invading pleura, pericardium and 
diaphragm are considered resectable and those invading other structures such as the trachea 
and aorta are considered unresectable [1, 26]. 
 
 
Image 3. T2 N1 Esophageal tumor; the mass can be seen invading through 4 of 5 esophageal 
layers. The adventitia is intact and there is no infiltration of tumor into adjacent structures. 
A recent meta-analysis and systematic review of 49 studies showed EUS to have a high 
pooled sensitivity for T staging between 81-90% with a pooled specificity of approximately 
99%. The pooled sensitivity and specificity of EUS for assessing tumor depth per T stage 
were 81.6% and 99.4% for T1, 81.4% and 96.3% for T2, 91.4% and 94.4% for T3, and 92.4% 
and 97.4% for T4 [13]. 
3.2 Determining the N stage 
EUS has a high accuracy for detecting regional lymph node involvement with a high 
sensitivity and specificity (85% and 85% respectively in a recent meta-analysis). FNA 
significantly improves the diagnostic capability of EUS for detecting malignant lymph nodes 
(sensitivity of 97% and specificity of 96%) by adding cytological analysis [13]. The 
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characteristics of a malignant node are size greater than 1 cm, rounded shape, sharp 
borders, and homogenous hypoechogenicity [5]. Malignant lymph nodes are usually in close 
proximity to the esophageal mass and often FNA can be impeded by the mass if in the 
trajectory of the needle. A selective approach to EUS-FNA may be applied by use of the 
modified EUS criteria for lymph node staging (standard characteristics plus EUS identified 
celiac lymph nodes, >5 lymph nodes, or EUS T3/4 tumor) for increased accuracy and 
decreased need for FNA (and cost) [27]. 
Regional lymph nodes are defined as any para-esophageal node extending from cervical 
nodes to celiac nodes. The number of involved lymph nodes--instead of their location--has 
been found to have prognostic implications [28-30]. This led to a revision of the N 
classification to support groupings of number of positive nodes as follows:  N0 (none), N1 
(1–2), N2 (3–6), and N3 (≥7) [14]. The examination for metastatic lymph nodes begins with 
examination of the celiac axis and the diaphragmatic crurae and continues as the scope is 
withdrawn through the esophagus. Peri-tumoral lymph nodes should be noted during 
determination of the T stage and the remainder of the mediastinum should be carefully 
examined as the scope is withdrawn.  
3.3 Determining the M stage 
The liver is the most common site of distant metastases of esophageal cancer. EUS can 
accurately evaluate the medial two thirds of the liver for metastases but cannot reliably 
exclude metastases in the entire liver [7]. CT and PET are most commonly used to evaluate 
for distant metastases. The role of EUS is greatest in confirming the presence of metastases 
in distant lymph nodes or lesions in the liver. The accuracy is increased by FNA and 
cytological evaluation of liver lesions as small as 4 mm [31-33]. Careful examination of the 
liver should be performed during staging for occult metastases not identified by other 
imaging studies. Identification of occult lesions may be low but can change the management 
of the patient. Any focal, discrete hypoechoic lesion of the liver identified should be 
sampled by EUS [34].  
Malignant celiac lymph nodes are no longer considered metastatic and are grouped with 
regional lymph nodes. M classification is simply designated as M0 for no distant metastases, 
and M1 for presence of distant metastases [14]. 
4. Restaging following neoadjuvant therapy 
The overall accuracy of EUS to assess the response to neoadjuvant chemotherapy or 
chemoradiotherapy is much less accurate than for initial staging and its role for this purpose 
is debatable [35, 36]. The presence of inflammation and fibrosis that remains following 
neoadjuvant therapy can be indistinguishable from residual tumor and may result in 
overstaging by EUS. Alternatively, residual microfoci of tumor in the esophageal wall may 
result in understaging [37]. Reduction of tumor thickness by > 50% is associated with a 
response to therapy and nodal status following neoadjuvant therapy has been shown to 
predict survival [36, 38, 39]. 
5. Staging of gastric tumors 
Patients with gastric cancer often present with advanced disease at the time of diagnosis, 
which is usually unresectable. Distant metastases and/or involvement of major blood 
vessels usually indicate unresectability. EUS is one of the primary means for loco-regional 
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staging of gastric cancers. Patients typically present with abdominal pain, nausea, early 
satiety, anorexia and weight loss that warrants an initial upper endoscopic evaluation. In 
addition, gastric cancers are often diagnosed endoscopically when a CT scan is performed 
and notes a thickened gastric fold or a non-healing ulcer. EUS is then performed for further 
loco-regional staging.  
The choice of echoendoscope for evaluation of gastric tumors is dependent on the location of 
the tumor and often a personal preference of the endosonographer. Obtaining adequate 
acoustic coupling between the gastric wall and the transducer can present a challenge. It is 
critical to remove all of the air from the stomach and instill up to 500 mL of water in order to 
adequately evaluate lesions (especially if the lesion is small). Changing the patient’s 
position, such as placing the patient in a reverse Trendelenberg position to evaluate a lesion 
in the antrum, is often necessary to allow the water to pool in the targeted area. Care must 
be taken in preventing aspiration as these patients are sedated and thus possess a 
diminished gag reflex. A radial echoendoscope operating between 7.5 and 10 MHz allows 
for adequate sonographic views of the gut wall with visualization of all 5 wall layers. Some 
endosonographers prefer a linear echoendoscope since it allows for FNA of lymph nodes 
without having to change endoscopes. Lastly, if a smaller lesion such as an early gastric 
cancer is encountered, a high-frequency ultrasound probe may provide the highest 
resolution to determine depth of invasion. 
5.1 Determining the T Stage 
EUS remains as the diagnostic tool of choice for evaluation of tumor depth in gastric cancer. 
This holds true especially in differentiating between early to intermediate (T1-2) and 
advanced (T3-4) primary tumors [40]. Gastric masses usually appear as irregular, poorly-
circumscribed hypoechoic masses. The depth of invasion is determined by the penetration 
into one of the sonographic layers. It is important to note the integrity of each of these layers 
as described below. 
The 7th edition of the AJCC gastric cancer staging system applies to tumors arising in the 
more distal stomach, and those arising in the proximal 5 cm without crossing the 
esophagogastric junction [41]. Tumors confined to the mucosa and submucosa (T1), 
regardless of the N stage, are considered early gastric cancer [42]. Tis is the earliest stage and 
reserved for intraepithelial tumors without invasion of the lamina propria [1]. The T1 
category is further subdivided into T1a for invasion of lamina propria or muscularis 
mucosa, and T1b for invasion of submucosa [41]. The distinction between Tis, T1a and T1b 
is important in deciding whether endoscopic resection is feasible. Contrary to staging in 
other parts of the GI tract, invasion of the lamina propria is classified as T1a rather than Tis 
since there is an abundance of lymphatic channels in the gastric mucosa, and thus associated 
lymph node metastases are possible when the tumor is confined to the lamina propria [41]. 
In areas with a high prevalence of gastric cancers, such as Japan and Korea, endoscopic 
mucosal resection (EMR) and endoscopic submucosal dissection (ESD) is widely employed 
as a safe and minimally invasive curative technique [43-46]. 
Invasion of the muscularis propria by tumor is considered T2 [1]. Sonographically, these 
lesions will involve the fourth layer (muscularis propria) without penetrating the fifth layer 
(serosa). Distinguishing between a T2  and T3 tumor can be difficult at times due to the 
subtle differences in the visualized gastric layers. Once the tumor has penetrated the fifth 
sonographic layer without invasion of visceral peritoneum or adjacent structures, it is 
classified as T3. In contrast to a T2 tumor, a T3 tumor will have irregular margins, often 
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appearing as finger-like projections, or pseudopodia, extending into the gastrocolic or 
gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the 
visceral peritoneum covering these structures. T4 tumors are defined as those invading the 
serosa or adjacent structures, and they are divided into T4a for tumors invading the serosa 
(visceral peritoneum) and T4b for tumors invading adjacent structures such as spleen, 
transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small 
intestine, and retroperitoneum [1, 41].  
 
 
Image 4. T3 gastric adenocarcinoma with infiltration of the tumor beyond the 4th 
sonographic layer without penetration of the visceral peritoneum. 
A recent meta-analysis reviewed the available literature for the performance of EUS in 
staging of gastric cancer. The overall sensitivity for individual T stages ranged from 86% (for 
T3) to 65% for T2), and specificity of 96% (for T1) to 85% (for T3). An important observation 
of this meta-analysis was the high performance rates for differentiating between early to 
intermediate (T1-2) and advanced (T3-4) primary gastric tumors which may guide 
therapeutic management [40].  
5.2 Determining the N stage 
Similar to the newly adopted definition for N stage in staging of esophageal cancer, gastric 
cancer N stage classification is based on the number of regional lymph nodes as follows: N0 
(none), N1 (1-2), N2 (3-6), N3 (7 or greater). The necessity to count the number of lymph 
nodes, as well as the heterogeneity in the criterion for nodes regarded as malignant, present 
a difficult challenge in assessing for nodal involvement. Scanning for peri-gastric lymph 
serosa 
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nodes should begin from the antrum to the gastroesophageal junction with the balloon 
distended and the gastric lumen compressed. Water can be instilled to aid in the 
visualization if a large amount of air artifact is seen. Malignant lymph nodes are usually 
regarded as round, hypoechoic, sharp and greater than 1 cm [5]. Although one study of 
resected gastrectomy specimens showed that 55% of metastasis-containing nodes were less 
than 5 mm, suggesting that lymph node size is not a reliable predictor of metastases in 
gastric cancer [47]. 
5.3 Determining the M stage 
EUS is not suitable for detecting distant metastases but is sensitive in evaluating portions of 
the liver for metastatic disease and for malignant ascites. Various studies have shown that 
the detection of ascites by EUS in patients with gastric cancer is associated with peritoneal 
metastases [48-50]. Ascites appears as anechoic, triangular shaped collections of fluid in the 
peri-hepatic or peri-gastric regions. FNA can be formed for cytological evaluation. Care 
must be taken not to cross the tumor in order to obtain the fluid. This may produce a falsely 
positive result and also contaminate the fluid with malignant cells. Prophylactic antibiotics 
should be administered and continued post-procedure. Positive peritoneal cytology is 
classified as M1 [41].   
6. Infiltrating gastric malignancies 
Infiltrating malignancies of the stomach include the diffuse type of gastric adenocarcinoma 
(linitis plastica) and primary gastric lymphomas (PGL). EUS is important in determining the 
depth of involvement of these lesions. The normal gastric thickness is between 3 to 5 mm 
and appears thickened in infiltrating tumors. Sonographic images in linitis plastica will 
either show a homogenous appearance across all the layers of the gastric wall making the 
individual layers indistinguishable, or will appear as thickening of the third and fourth 
sonographic layer (submucosa and muscularis propria).   
Benign conditions can often mimic malignant conditions by presenting with thickened 
gastric folds, such as in protein-losing hypertrophic gastropathy (Ménétrier's disease), 
amyloidosis and Zollinger-Ellison syndrome. EUS will usually reveal thickening limited to 
the first and second sonographic layer indicating a mucosal disease. Large capacity and 
jumbo forceps biopsy can often provide sufficient tissue to aid in the diagnosis of these 
disorders. For lesions involving the third and fourth sonographic layers, deep endoscopic 
biopsies (using a bite-on-bite technique) or full-thickness surgical biopsies are often 
necessary to make a diagnosis. A few case reports and studies have shown EUS-FNA as a 
feasible technique for obtaining tissue samples from thickened folds or other lesions within 
the GI tract wall, especially when endoscopic biopsies are negative. One retrospective study 
of EUS-FNA in evaluating intramural and extramural GI tract lesions showed the 
sensitivity, specificity, and diagnostic accuracy of EUS-FNA in diagnosing GI tract 
neoplastic lesions were 89%, 88%, and 89%, respectively[51]. 
The staging of PGL is different than for gastric adenocarcinoma and utilizes either the 
modified Ann Arbor staging system or the modified TNM staging system named the Paris 
classification [52, 53]. Sonographic appearance of PGL varies and can mimic other 
infiltrative diseases both benign and malignant. The appearance may be of a focal nodular 
infiltration of the mucosa, or as diffuse hypoechoic thickening of the mucosal layers (first 
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and second sonographic layers) with fusion of these layers as the tumor extends [7, 54]. 
There is limited data in the literature regarding EUS for staging gastric lymphoma but it is 
generally accepted as the most accurate method to determine local stage. T stage accuracy 
has been reported between 80-92% and N stage between 77-90% [55]. FNA with flow-
cytometry of the aspirate may aid in the detection of metastatic lymph nodes and guide 
further management. The role of EUS in the follow-up of gastric lymphomas is not well-
defined in the literature and we do not routinely employ its use in the absence of further 
studies. 
 
 
Image 5. Infiltrating gastric adenocarcinoma with thickening of the submucosa and 
muscularis propria. 
7. Staging of ampullary tumors 
Carcinomas of the ampulla of Vater are rare and can arise from the major papilla, pancreas, 
duodenum and the common bile duct. EUS is useful in evaluating the depth of invasion of 
ampullary tumors and it aids in determining whether endoscopic resection is feasible. Like 
colon polyps, these lesions follow the adenoma-carcinoma sequence. Benign adenomas of 
the ampulla should be removed entirely by endoscopic ampullectomy. Conversely, 
malignant or invasive lesions should be removed surgically, often requiring a 
pancreaticoduodenectomy for complete resection. Patients with ampullary carcinomas 
typically present with obstructive jaundice or pancreatitis. Occasionally they are found 
incidentally by upper endoscopy. 
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Classification according to the 7th Edition of the AJCC staging system for tumors of the 
ampulla of Vater is as follows: Tis corresponds to carcinoma in situ, T1 tumors are limited to 
the ampulla of Vater or sphincter of Oddi, T2 tumors invade the duodenal wall, T3 tumors 
invade the pancreas, and T4 tumors invade peri-pancreatic soft tissues or other adjacent 
organs or structures other than the pancreas[1].  
Sonographic imaging of the ampulla of Vater can be performed either with a radial or 
linear-array echoendoscope. Once the echoendoscope is advanced to the second portion of 
the duodenum, it should be withdrawn slowly while scanning for the ampullary lesion. The 
balloon should be filled just enough as not to press on the ampullary lesion and water 
should be instilled into the duodenum for improved echogenic coupling. An alternative 
method is to visualize the ampullary lesion endoscopically and place the water-filled 
balloon directly on the lesion. A combination of both approaches may yield the best results. 
The ampulla appears as a hypoechoic structure arising from the wall of the duodenum 
usually measuring 8 to 12 mm. Ampullary tumors are hypoechoic masses at the ampulla 
which create loss of interface between the different echogenic layers of the duodenal wall. 
The sphincter of Oddi may be difficult to visualize but would appear as a thin hypoechoic 
layer surrounding the pancreaticobiliary duct. Extension of the hypoechoic mass within the 
biliary or pancreatic duct lumen, or wall thickening of the duct, suggests ductal infiltration 
[7, 56].  
The diagnostic accuracy of EUS in ampullary tumor staging is reportedly 0–100% for T1, 45–
100% for T2, and 75–100% for T3–T4 lesions with an overall accuracy in tumor staging from 
62 and 90% [57]. Decreased accuracy and understaging has been reported when a biliary 
stent is present. 
Intraductal ultrasound (IDUS) is yet another method of visualizing ampullary tumors by 
use of a high-frequency ultrasound probe (20-30 MHz) inserted into the bile duct during 
ERCP. Various studies have shown superior T staging for IDUS compared to EUS [56, 58, 
59], with overall accuracy for tumor staging ranging between 78-88% for IDUS. Limitations 
of IDUS include the necessity of ERCP for staging and cannulation of the bile duct (which 
may be difficult with larger tumors), cost of the probe, potential damage to the probe by the 
duodenoscope elevator, and its limited availability.  
Nodal metastases are best evaluated by EUS as it has been shown to have superior 
accuracy for detection of malignant lymph nodes compared to transabdominal ultrasound 
and CT [60-62]. MRI may show equal or improved lymph node detection. CT is superior 
for detection of distant metastases. The technique for malignant lymph node detection 
involves scanning the peri-pancreatic regions for any suspicious nodes. Regional lymph 
nodes (N1) are peri-pancreatic nodes including:  hepatic, hepatic artery, epiploic, omental, 
peri-portal,  infra-pyloric,  celiac, superior mesenteric, retroperitoneal, and lateral aortic 
(lumbar) nodes. Tumor involvement of other nodal groups such as splenic and para-aortic 
lymph nodes and those at the tail of the pancreas are not regional and classified as distant 
metastases (M1) [1]. FNA can be performed of any malignant appearing lymph nodes for 
cytological analysis. 
8. Staging of duodenal tumors 
Non-ampullary duodenal adenocarcinomas are exceedingly rare accounting for 1-2% of all 
GI malignancies and 25-50% of all small intestinal cancers. Adenocarcinomas are the most 
common followed by carcinoid tumors [1, 63, 64].  
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Duodenal tumors are staged using the 7th edition of the AJCC for Small Intestine Cancer.[1]  
The role of EUS in staging these tumors is not well-defined and has not been widely studied. 
Depending on the size of the tumor, a radial echoendoscope or a high-frequency ultrasound 
probe can be utilized to assess depth of invasion for T staging. In order to obtain accurate 
imaging of the 5 sonographic layers of the duodenal wall, all of the air should be aspirated 
out of the lumen and the tumor should be submerged in water. 
Nodal status is an important predictive factor for recurrence and survival in patients with 
resectable duodenal adenocarcinoma [64]. EUS can aid in the assessment of regional lymph 
nodes by counting and possibly performing FNA of suspicious nodes. 
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